Roswell is delivering the $100, 1-hour Genome for precision medicine. Simple, fast, low cost and with clinical-grade accuracy including phasing, assembly and direct reading of epigenetic data.
In 2019, Roswell Biotechnologies, Inc., the pioneer in the development of a molecular electronics platform for DNA Sequencing, closed a $32 million round of Series A financing backed by multiple investors.
Going "on-chip" to deploy bio-sensors provides unprecedented economics, precision, portability, and scalability. The first chip is designed to read DNA; future chips will be designed for protein detection and other diverse bio-sensing applications.